Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance

ABSTRACT: Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance

PROVIDER: PRJNA879768 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21536545_1.fastq.gz	Fastqsanger.gz
	SRR21536545_2.fastq.gz	Fastqsanger.gz
	SRR21536546_1.fastq.gz	Fastqsanger.gz
	SRR21536546_2.fastq.gz	Fastqsanger.gz
	SRR21536547_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance in Ovarian Cancer

Project description:Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance in Ovarian Cancer

| PRJNA932806 | ENA

The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFNb pathway Phospho

Project description:Phosphoproteomics show that the tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFNb pathway

2021-01-15 | MSV000086706 | MassIVE

The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFNb pathway Proteome

Project description:Proteome analysis reveals that the tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFNb pathway Proteome

2021-01-15 | MSV000086708 | MassIVE

Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance

Project description:ST3GAL3 is a α2,3-sialyltransferase and involves in α2,3 sialylation in tumors; however, its role in the tumorigenic capacity of malignant cells and anti-tumor immune remains largely unexplored. Here, HM1 cells were stably transfected using lentivirus expressing a shRNA targeting ST3GAL3 (HM1-shST3GAL3) or scramble shRNA as control (HM1-shControl). Then, HM1-shControl or HM1-shST3GAL3 cells were injected into the right flank of B6C3F1 mice using a 27 g needle. ST3GAL3 knockdown significantly compromised tumor growth at a immune-dependant manner. Mechanistically, ST3GAL3 knockdown enhances pro-inflammatory phenotype of macrophages, leading ultimately to activation and recruitmentof CD8+ T cells. Moreover, we identified ST3GAL3 as a potential novel biomarker for bevacizumab or immune checkpoint blockade (ICB) intervention. ST3GAL3 knockdown in tumors also be useful to improve cancer immunotherapies.

2023-05-09 | GSE213219 | GEO

Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance in Ovarian Cancer

2023-05-09 | GSE224856 | GEO

Tumor cell-intrinsic ATP6V0A1 drives immunosuppressive reprogramming in colorectal cancer

Project description:Tumor cell-intrinsic ATP6V0A1 drives immunosuppressive reprogramming in colorectal cancer

| PRJNA997948 | ENA

BMI1 dynamic balance destroy blunts immunotherapy efficacy in HCC

Project description:BMI1 dynamic balance destroy blunts immunotherapy efficacy in HCC

| PRJNA913003 | ENA

Systematic identification of tumor-intrinsic resistance mechanisms and combinatorial therapy targets for immunotherapy

Project description:A number of reports have demonstrated that tumor-intrinsic mechanisms of resistance, such as the loss of genes critical for antigen presentation and inflammatory responses, along with the activation of various cellular signaling cascades, can limit the efficacy of immunotherapy. Strategies to sensitize tumor cells to immunotherapy may overcome some resistance mechanisms, but identifying therapeutic targets has remained challenging. Here, we integrate a two-cell type (2CT) whole-genome CRISPR-Cas9 screen with dynamic transcriptional profiling of the tumor/T cell interaction to comprehensively identify tumor genes that are induced to promote tumor survival. We assessed the therapeutic potential of pharmacological inhibition of these and other top CRISPR identified targets as combinatorial targets to improve the efficacy of tumor destruction by T cells.

2022-08-31 | GSE137824 | GEO

Disruption of BMI1 dynamic balance blunts immunotherapy efficacy in HCC

Project description:Disruption of BMI1 dynamic balance blunts immunotherapy efficacy in HCC

| PRJNA911277 | ENA

Systematic identification of tumor-intrinsic resistance mechanisms and combinatorial therapy targets for immunotherapy

Project description:Systematic identification of tumor-intrinsic resistance mechanisms and combinatorial therapy targets for immunotherapy

| PRJNA573537 | ENA